These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20975385)

  • 1. ERCC1 and small cell lung cancer.
    Rossi G; Nannini N; Tiseo M
    J Thorac Oncol; 2010 Nov; 5(11):1876-7. PubMed ID: 20975385
    [No Abstract]   [Full Text] [Related]  

  • 2. Excision repair cross-complementing-1 for small cell lung cancer.
    Kim YH; Ishii G; Ochiai A
    J Thorac Oncol; 2011 Mar; 6(3):652; author reply 652. PubMed ID: 21317752
    [No Abstract]   [Full Text] [Related]  

  • 3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
    Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
    J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
    Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelioma and small cell lung cancer.
    Tsao AS; Heymach J
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
    [No Abstract]   [Full Text] [Related]  

  • 7. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin.
    Olaussen KA
    Cancer Biol Ther; 2009 Oct; 8(20):1922-3. PubMed ID: 19713753
    [No Abstract]   [Full Text] [Related]  

  • 8. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
    Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
    J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair by ERCC1 in non-small-cell lung cancer.
    Cecere F; Bria E; Rosell R
    N Engl J Med; 2006 Dec; 355(24):2590-1; author reply 2591. PubMed ID: 17167144
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA repair by ERCC1 in non-small-cell lung cancer.
    Grenader T; Shavit L
    N Engl J Med; 2006 Dec; 355(24):2591; author reply 2591. PubMed ID: 17167936
    [No Abstract]   [Full Text] [Related]  

  • 13. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA repair by ERCC1 in non-small-cell lung cancer.
    Wilcox JE
    N Engl J Med; 2006 Dec; 355(24):2590; author reply 2591. PubMed ID: 17171818
    [No Abstract]   [Full Text] [Related]  

  • 17. Small cell lung cancer in never smokers: report of two cases.
    Antony GK; Bertino E; Franklin M; Otterson GA; Dudek AZ
    J Thorac Oncol; 2010 May; 5(5):747-8. PubMed ID: 20421768
    [No Abstract]   [Full Text] [Related]  

  • 18. ERCC1 measurements in clinical oncology.
    Reed E
    N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
    [No Abstract]   [Full Text] [Related]  

  • 19. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
    Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
    Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro A
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.